Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, randomized, double-blind, placebo- and comparator-controlled, multicenter trial to evaluate the efficacy of increasing doses of SRP-001 for treating acute pain

Next Previous
Trial Profile

A Phase 2, randomized, double-blind, placebo- and comparator-controlled, multicenter trial to evaluate the efficacy of increasing doses of SRP-001 for treating acute pain

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRP 001 (Primary)
  • Indications Acute pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors South Rampart Pharma

Most Recent Events

  • 10 Apr 2025 According to South Rampart Pharma media release, the company expects to deliver critical proof-of-concept results within 12 months, positioning SRP-001 as a transformational solution in the rapidly expanding pain management market projected to surpass $40 billion by 2030.
  • 16 May 2024 According to South Rampart Pharma media release, the company plans to initiate this trial in second half of 2024.
  • 29 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top